Stocks · News reference
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 8:22 PM
- Checked
- Aug 11, 2026, 8:22 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?
The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.
Read original at the-motley-foolKLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’
Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb.
Read original at benzingaB. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11
B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.
Read original at benzingaUPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of $(0.57) per share from
Read original at benzingaMacrogenics Q2 EPS $(0.31) Misses $0.02 Estimate, Sales $32.832M Miss $67.456M Estimate
Read original at benzinga